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Conclusion: Alteration of cellular signaling upstream of GSK-3β is respon-
sible for the lack of EPO protective effect in STZ-induced diabetic hearts.
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The aim of this work was to check the hypothesis that increased cardiac
aldosterone level combined with arterial hypertension may enhance the delete-
rious effects at the heart level. Transgenic mice overexpressing Aldo Synthase
(AS) in cardiomyocytes and wild type (WT) littermates were submitted to
AngII-induced hypertension by osmotic pump (1mg/kg/day) during 3 or
8 weeks.
Results: 1) Physiological analysis indicated that the arterial pressure
increased similarly (+50 mmHg) in AngII-perfused groups whatever the geno-
type. At the ventricular level, the hypertrophy and the fibrosis (x3, p<0.05)
developed identically in the 2 AngII-groups (p<0.05 versus matched groups)
independently of the time. In contrast, at the level of the atria, 3 wk AngII per-
fusion significantly worsened the dilatation +46% for AS mice and +33% for
WT (p<0.05 versus matched groups) and fibrosis in AS mice (+20% AngII AS
versus AngII WT, p<0.05). In the 8 wk perfused groups, the atrial diameters
and the fibrosis were increased compared to 3 weeks. Besides, we noticed that
AngII increased more P wave duration in AS mice than in WT. Interestingly
Eplerenone treatment (50mg/kg/day) prevented all these changes.
2) The electrical changes led us to study the atrial expression of connexin
(Cx) 40 and 43. In AS mice at basal state, we found a 4-fold increase in func-
tional Cx43 when compared to WT whereas the functional levels of Cx40
were similar in both groups. In AngII-mice we found a decrease of functional
Cx40 (–50% and –40% in AS and WT mice, respectively) whereas functional
Cx43 increased by 30% whatever the genotype.
In conclusion, we show for the first time that both cardiac aldosterone and
AngII regulate the expression of Cx40 and 43 in mouse left atria. In addition
our results suggest that cardiac aldosterone worsened the deleterious effects of
AngII-induced hypertension on left atria, through increases in dilatation,
fibrosis and it increases conduction time.
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Background: Genetically modified mice offer the unique opportunity to
gain insights into the pathophysiology of pulmonary arterial hypertension
(PAH). In mice, right heart catheterization is the only available technique to
measure right ventricular systolic pressure (RVSP). However, it is a terminal
procedure and does not allow serial follow-up. Our objective was to validate
a non-invasive technique to assess RVSP in mice.
Methods: Right ventricle catheterization and echocardiography were simul-
taneously performed in mice with pulmonary hypertension induced acutely by
infusion of a thromboxane analogue, U-46619 or chronically by lung-specific
over-expression of interleukin 6 (IL-6). In a subgroup of mice, echocardio-
graphy was performed using light anesthesia before catheterization. Pulsed-
Doppler of pulmonary artery flow was recorded in the parasternal short axis
view. Pulmonary acceleration time (PAT), and ejection time (ET) were mea-
sured.
Results: Infusion of U-46619 acutely increased RVSP, shortened PAT and
decreased PAT/ET. The pulmonary flow pattern changed from symmetric at
baseline to asymmetric at higher RVSPs. Transgenic IL-6 mice had high
RVSP measured by catheter (39±7 mmHg), short PAT (17±4 ms) and low
PAT/ET ratio (31±8%). The PAT correlated linearly with RVSP (r2=–0.67;
p<0.0001), as did PAT/ET (r2=–0.76, p<0.0001). Sensitivity and specificity for
detecting high RVSP (>32 mmHg) were 100% (7/7) and 86% (6/7), respec-
tively, for both indexes (cutoff values: PAT <21 ms and PAT/ET <39%).
PAT/ET measured during light anesthesia correlated with PAT/ET obtained
during invasive catheterization (r2=0.87, p<0.0001). Intra-observer and inter-
observer variability of PAT and PAT/ET were less than 6%.
Conclusion: Pulmonary artery systolic pressure can be estimated noninva-
sively in mice. Echocardiography allows to monitor acute changes of RVSP
and to detect pulmonary hypertension. This technique enables to follow PAH
evolution easily and repeatedly in mice.
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